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Abstract
Purpose Although evidence is building on the positive
effects of physical activity for prostate cancer survivors,
less is known about the possible independent effects of
sedentary behavior on quality of life and psychological
well-being in this population. We determined the extent to
which objectively measured moderate-to-vigorous physical
activity (MVPA) and sedentary behavior were indepen-
dently associated with quality of life, anxiety, and
depressive symptoms in prostate cancer survivors.
Methods An exploratory cross-sectional analysis was
undertaken on baseline data from a multicenter, cluster
randomized controlled trial on the efficacy of a clinician
referral and 12-week exercise program for men who had
completed active treatment for prostate cancer. Multiple
regression analyses were performed using data from 98
prostate cancer survivors who wore hip-mounted
accelerometers (time spent sedentary defined as \100
counts per minute [CPM]; MVPA defined as[1,951 CPM)
and completed self-report instruments on their quality of
life, anxiety, and depressive symptoms. Results were
compared with minimal clinically important differences for
the quality of life scales.
Results Independent of sedentary behavior, increases in
MVPA of between 15 and 33 min/day were associated with
clinically important (but not statistically significant)
improvements in three quality of life scales (insomnia,
diarrhea, and financial difficulties). Independent of MVPA,
decreases in sedentary behavior of 119 and 107 min/day
were associated with clinically important (but not statisti-
cally significant) improvements in physical functioning and
role functioning, respectively.
Conclusion Within our exploratory study, modest increa-
ses in MVPA and more substantive decreases in seden-
tary behavior were independently associated with
clinically important improvements in several quality of
life scales. Further research, including prospective stud-
ies, is required to understand sedentary behavior across
larger and more representative samples (in terms of their
physical, psychological, and social functioning and their
engagement in physical activity) of prostate cancer
survivors.
Trial registration Australia and New Zealand Clinical
Trials Register (ANZCTR): ACTRN12610000609055
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Sedentary behavior  Sedentary time  Prostate cancer
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Introduction
Prostate cancer is the second most common cancer in men
worldwide and has a high survival rate [1]. Having been
diagnosed with prostate cancer, however, is associated with
poorer mental health (e.g., increased anxiety, depressive
symptoms, and psychological distress) [2, 3], functional
limitations (e.g., urinary, bowel, and sexual dysfunction)
[4], low levels of moderate-to-vigorous physical activity
(MVPA) [5, 6], and reduced quality of life [2, 4]. Engaging
in physical activity can ameliorate many of the adverse
effects of prostate cancer and its treatments, with system-
atic review findings strongest for the positive effect of
physical activity on aerobic endurance, muscular endur-
ance, and quality of life in this population [7, 8]. Con-
versely, evidence is emerging that sedentary behavior
poses a health risk that is independent of insufficient
physical activity [9–11]. Sedentary behavior is defined as
‘‘any waking behavior characterized by an energy expen-
diture B1.5 METs [metabolic equivalents] while in a sit-
ting or reclining posture’’ [12]. From research with adults,
there is strong evidence that sedentary behavior is associ-
ated with all-cause mortality, fatal and non-fatal cardio-
vascular disease, type 2 diabetes, and metabolic syndrome
independent of physical activity [13]. Comparisons
between men with and without history of prostate cancer,
however, have yielded inconsistent findings with respect to
time spent sedentary [14, 15], and few studies have focused
on the association between sedentary behavior and health
outcomes (particularly mental health outcomes) in prostate
cancer survivors [5, 16]. Greater understanding of the
independent effects of physical activity and sedentary
behavior on the quality of life and psychological well-be-
ing of prostate cancer survivors is warranted and would
assist in the design of targeted interventions to improve the
lives of prostate cancer survivors.
The ENGAGE (efficacy of a referral and physical
activity program for survivors of prostate cancer) study was
a multicenter, cluster randomized controlled trial to deter-
mine the efficacy of a clinician referral and 12-week
exercise program to increase physical activity among men
who had completed active treatment for prostate cancer
[17, 18]. Compared to men in the control condition, those
in the intervention significantly increased their vigorous
physical activity levels and experienced increased cogni-
tive functioning and reduced depressive symptoms [18].
This trial is one of only a few studies involving prostate
cancer survivors that included measures of quality of life
and psychological well-being, as well as objective mea-
sures of physical activity and sedentary behavior. Given the
potential utility inherent in understanding these relation-
ships for the development and refinement of interventions
to improve health outcomes, we conducted a secondary
analysis of the ENGAGE study baseline data. The aim of
this exploratory cross-sectional analysis was to determine
the extent to which MVPA and sedentary behavior were
independently associated with quality of life, anxiety, and
depressive symptoms in prostate cancer survivors prior to
commencement of the exercise program. We also assessed
whether the associations found could be clinically
important.
Methods
Study population
The ENGAGE study recruitment and sample details have
been described previously [17, 18]. Inclusion criteria were
men diagnosed with stage I, II, or III prostate cancer who
had (a) completed active treatment for prostate cancer
within the previous 3–12 months (patients on hormone
treatment were eligible to participate), and (b) the ability to
complete surveys in the English language. Patients were
excluded if they had any musculoskeletal, cardiovascular,
or neurological disorders that could limit them from exer-
cising. Eligible patients were recruited through the outpa-
tient clinics of three large public health services and four
private clinics located in metropolitan Melbourne, Aus-
tralia. The patients’ treating clinicians provided medical
clearance for all participants prior to their involvement in
the exercise program. Of the 741 patients screened for this
study, 443 met the eligibility criteria, and 147 were con-
tactable and agreed to participate. Of these 147 partici-
pants, 98 provided complete accelerometer, quality of life,
anxiety, and depressive symptoms data (34 chose not to
wear accelerometers, 13 provided invalid accelerometer
data, and 2 had incomplete quality of life, anxiety, and
depressive symptoms data).
Ethics approval to conduct this study was obtained from
the human research ethics committees of the health ser-
vices and host university involved in this study. Informed
consent was obtained from all individual participants
included in the study.
Measurements
Baseline data on demographics, clinical characteristics,
quality of life, anxiety, depressive symptoms, physical
activity, and time spent sedentary were collected. Demo-
graphics and clinical characteristics obtained through self-
report questionnaires included: age, height, weight, rela-
tionship status, highest level of education, and treatment
regime. Self-reported heights and weights were used to
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calculate body mass index (BMI) (kg/m2) scores. Clinical
characteristics obtained from medical records included:
stage of disease, weeks since active treatment, and health
service type (public/private).
Quality of life was measured using the European
Organization for Research and Treatment of Cancer core
quality of life questionnaire (EORTC QLQ-C30(V3)) [19]
and the prostate tumor-specific module (EORTC QLQ-
PR25) [20]. The EORTC QLQ-C30(V3) has a global health
status scale, five functional scales (physical, role, cogni-
tive, emotional, and social), and nine symptom scales (fa-
tigue, nausea and vomiting, pain, dyspnea, insomnia,
appetite loss, constipation, diarrhea, and financial difficul-
ties). The EORTC QLQ-PR25 has two functional scales
(sexual activity and sexual functioning) and four symptom
scales (urinary symptoms, bowel symptoms, hormonal
treatment-related symptoms, and incontinence aid). Both
measures have convergent and discriminant validity, as
well as adequate internal consistency reliability [19, 20].
Minimal clinically important differences for the scales
(each of which ranges from 0 to 100) have been estimated
to be approximately 5–10 points [21–23]. This estimation
strongly overlaps with guidelines for small-sized, clinically
relevant differences (ranging from 3 to 7 points for diarrhea
to 6–19 points for role functioning) produced from a
method combining a systematic review, a meta-analysis,
and expert opinions [24].
Anxiety was measured with the Memorial Anxiety Scale
for Prostate Cancer (MAX-PC) [25]. The MAX-PC has
three subscales (prostate cancer anxiety, prostate-specific
antigen anxiety, and fear of recurrence) and a total anxiety
scale. The MAX-PC has concurrent validity with estab-
lished anxiety measures (e.g., the anxiety subscale of the
Hospital Anxiety and Depression Scale [26]), discriminant
validity, internal consistency, and test–retest reliability
[25, 27].
Depressive symptoms were measured using the Centre
for Epidemiological Studies Depression Inventory (CES-
D) [28]. The scale has strong concurrent validity with both
clinical and self-report criteria, and sound construct
validity [28].
Physical activity and time spent sedentary were mea-
sured using hip-mounted ActiGraph GT1 M (Pensacola,
FL) units. The accelerometer is a valid and reliable tool for
measuring physical activity and sedentary time among
adults [29–31]. Each participant was shown how to wear
the accelerometer on a nylon belt over the right hip
(physical activity estimates do not vary by right or left hip
placement [32]) and was also provided with written
instructions on the use of the accelerometer. Participants
were asked to start wearing the accelerometer when they
got out of bed the next morning and asked to wear it for
seven consecutive days during waking hours. On
completion of the seven days, participants were asked to
return the accelerometer in a reply-paid envelope. Data
from the ActiGraph units were processed using ActiLife
software (V6.7.1) and managed using a customized
Microsoft Excel macro. Time spent sedentary was defined
as\100 counts per minute [CPM], and MVPA was defined
as[1,951 CPM [30]. To be included in the analysis, par-
ticipants were required to have worn the accelerometer for
at least 10 h each day (60 min or more of consecutive zero
counts, without ‘‘tolerance,’’ was considered non-wear of
the device) for at least four of the seven days (based on
Healy et al. [31]). Average daily minutes in MVPA and
time spent sedentary were calculated for each participant
based on the number of valid days of data provided. Due to
differences in daily accelerometer wear time between
participants, sedentary behavior was standardized to a 12-
hour wear time using the formula:
time spent sedentary
accelerometer wear time
 60min 12 h
This standardized sedentary behavior variable was used
in the analyses.
Current guidelines suggest that prostate cancer survivors
engage in at least 150 min/week of moderate-intensity
physical activity or 75 min/week of vigorous-intensity
physical activity or an equivalent combination of moderate
and vigorous physical activity, which may include weight-
bearing exercises [33].
Statistical analysis
Statistical analyses were performed using Stata (Version
13) software. Independent t tests and Chi-squared tests
were used to determine whether there were differences
between men with and without complete data in terms of
their demographic and clinical characteristics. Subsequent
analyses were performed on the data from the men with
complete data.
The sexual functioning and incontinence aid scales were
omitted from the analysis due to a high amount of non-
responses (62.2 and 70.4 %, respectively). Responding to
these items was conditional on participants being sexually
active in the last 4 weeks and wearing incontinence aids,
respectively. For the remaining variables, a negligible
amount of data were missing (\0.01 %). The result from
Little’s [34] test (v2(390) = 399.21, p = .36) suggests that
data were missing completely at random.
Using multiple regression analyses, MVPA and stan-
dardized sedentary behavior (as continuous variables) were
simultaneously regressed against each of the quality of life,
anxiety, and depressive symptoms scales and subscales.
Adjusted multiple regression analyses were also performed
with demographic variables (age, BMI, relationship status,
Cancer Causes Control
123
and highest level of education), clinical variables (number
of comorbidities, weeks since active treatment, stage of
disease, treatment regime, and health service type), and
clinician (to assess the effect of clustering) screened as
potential covariates or factors. Variables that were related
(p B .10) to any of the quality of life, anxiety, and
depressive symptoms scales and subscales in bivariate
analyses were included in the initial adjusted regression
models. Using backward elimination, covariates and fac-
tors were then removed from these models (one by one, in
an iterative process) when p C .05. Because these analyses
focused on estimation, rather than prediction, attention is
paid to the unstandardized beta coefficients and their con-
fidence intervals (rather than effect sizes for the propor-
tions of variance explained). The unstandardized beta
coefficients represent the changes in quality of life, anxiety,
and depressive symptom scores per 1 min/day increase in
MVPA or standardized sedentary behavior after adjusting
for the other covariates and factors included in each model.
Exact p values are reported together with unstandardized
beta coefficients and their confidence intervals. Although
adjusting the a value to protect against inflation of exper-
iment-wise error when multiple tests are performed is
generally advisable [35, 36], making such an adjustment in
this study could result in Type II errors, which may dis-
courage researchers from further investigations in this area.
Given that our prime focus was on hypothesis generation,
rather than hypothesis validation, we did not adjust for
multiple comparisons. Accordingly, a was set at 0.05.
Sample size calculations for the ENGAGE study were
based on the primary outcomes for the main trial [17, 18],
rather than the exploratory secondary analyses reported
here. Modest recruitment and the constraints of fixed-term
funding meant that the target of recruiting 220 participants
[17] was not achieved.
Given that the study was exploratory, we also assessed
whether the associations could be clinically important,
irrespective of their statistical significance. A minimal
clinical important difference can be defined as ‘‘the
smallest difference in score in the domain of interest which
patients perceive as beneficial and which would mandate,
in the absence of troublesome side effects and excessive
cost, a change in the patient’s management’’ [37]. The
results from the multiple regression analyses were com-
pared with minimal clinically important differences for the
quality of life scales using two methods. First, the changes
in MVPA and, separately, in sedentary behavior needed to
obtain minimal clinically important differences were cal-
culated. Minimal clinically important differences in quality
of life scales were defined as the lower limits of the ranges
for small-sized, clinically relevant differences provided in
published guidelines [24]. A small-sized difference is one
that is subtle, but clinically relevant. For each scale, the
changes in MVPA per day, and (separately) in sedentary
behavior per day, needed to obtain clinically important
differences were calculated by dividing the small-sized
clinically important difference by the adjusted unstan-
dardized beta coefficients. Second, the changes in quality
of life scores from performing recommended levels of
MVPA were determined. Prostate cancer survivors are
recommended to undertake at least 150 min/week of
moderate physical activity or 75 min/week vigorous
physical activity or an equivalent combination of moderate
and vigorous physical activity [33, 38, 39]. For the purpose
of this analysis, this guideline was translated into a daily
recommendation of 21 min (150 min/7 days) of MVPA.
For each scale, the effect of performing recommended
levels of MVPA was calculated by multiplying the daily
recommendation for MVPA (21 min/day) and the adjusted
unstandardized coefficient. Using published guidelines, the
resulting change in quality of life score was interpreted as
being trivial (no difference or unlikely to have clinical
relevance), small (subtle, but nevertheless clinically rele-
vant), medium (likely to be clinically relevant), or large
(unequivocal clinical relevance) [24]. The analysis did not
include the anxiety or depressive symptoms scales,
because, as far as we are aware, clinically important dif-
ferences for these scales have yet to be established.
Results
Participant demographic and clinical characteristics are
provided in Table 1. Briefly, the men had a mean age of
65.6 years (SD = 8.5), were overweight (BMI: M = 28.0,
SD = 3.7), and had last undergone active treatment, on
average, 25.3 weeks prior (SD = 10.0). Compared to men
who did not have complete data (n = 49), those with
complete data (n = 98) were, on average, 5 years older
(p\ . 01) and had undergone different treatment regimes
(i.e., more likely to have been treated with both surgery and
radiotherapy and less likely to have undergone surgery
only; p = .04) (see Table 1). There were no statistically
significant differences for BMI, relationship status, highest
level of education, number of comorbidities, weeks since
active treatment, stage of disease, and health service type.
Participants wore the accelerometers, on average, 14 h/day
(SD = 1.4) for between 4 and 8 days (M = 6.5,
SD = 0.9). They spent, on average, 38 min/day (SD = 22)
engaged in MVPA and 10 h/day (SD = 1.5) in sedentary
behavior (standardized for accelerometer wear time to
9 h/day, SD = 0.8).
In general, unstandardized beta coefficients for associ-
ations between MVPA and quality of life, anxiety, and
depressive symptoms scales and subscales were larger than
those between sedentary behavior and these variables
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(Table 2). None of the analyses returned statistically sig-
nificant results, however.
Interpretation of the unstandardized beta coefficients
with reference to guidelines for minimal clinically impor-
tant differences in quality of life scores revealed that an
increase in MVPA of less than 1 hour per day was asso-
ciated with clinically important (but not statistically sig-
nificant) differences in several symptom scales (fatigue,
insomnia, diarrhea, and financial difficulties; Table 3).
Undertaking recommended levels of MVPA (i.e.,
21 min/day, equivalent to 150 min/week) was only related
(but not to a statistically significant level) to reductions in
insomnia and financial difficulties to a clinically important
extent.
Discussion
Within our small study population of prostate cancer sur-
vivors, achievable increases in MVPA and reductions in
sedentary behavior were associated with clinically
important improvements in several aspects of quality of
life. These findings support evidence from randomized
controlled trials (synthesized in a recent systematic review
[40]) showing a positive relationship between physical
activity and quality of life in prostate cancer survivors. Our
work extends current knowledge through (1) demonstrating
the potential independent benefits of increasing MVPA and
reducing sedentary behavior for improving quality of life,
(2) providing evidence of such relationships when activity
levels are objectively measured, and (3) interpreting these
effects with reference to minimal clinically important
differences.
The magnitudes of the adjusted unstandardized beta
weights for the associations between both MVPA and
sedentary behavior and both physical functioning and
fatigue suggest that clinically important changes on these
quality of life scales may be achievable for many men with
prostate cancer. Although increasing MVPA by
52–78 min/day or reducing sedentary behavior by
119–132 min/day may be beyond many men with prostate
cancer, the independence of these effects suggests that
Table 1 Comparison of
demographic and clinical
characteristics of men with and
without complete data
Characteristics Complete data available Effect size p
Yes (n = 98) No (n = 49)
Demographic characteristics
Age, M (SD) years 67.3 (8.0) 62.1 (8.6) d = 0.62 \.01
Body mass index, M (SD) kg/m2 27.9 (3.7) 28.3 (3.6) d = -0.10 .57
Relationship status V = 0.10 .21
Married/partnered, n (%) 83 (84.7) 35 (76.1)
Separated/divorced/widowed/single, n (%) 15 (15.3) 11 (23.9)
Highest level of education V = 0.14 .23
Primary/secondary school, n (%) 33 (34.0) 22 (47.8)
Certificate or diploma, n (%) 37 (38.1) 12 (26.1)
University degree, n (%) 27 (27.8) 12 (26.1)
Clinical characteristics
Number of comorbidities, M (SD) 1.8 (1.5) 1.9 (1.3) d = -0.06 .76
Weeks since active treatment, M (SD) 26.1 (10.1) 23.7 (9.7) d = 0.24 .17
Stage of disease V = 0.07 .77
Stage I, n (%) 33 (38.8) 15 (40.5)
Stage II, n (%) 36 (42.4) 17 (45.9)
Stage III, n (%) 16 (18.8) 5 (13.5)
Treatment regime V = 0.24 .04
Surgery only, n (%) 37 (37.8) 27 (55.1)
Radiotherapy only, n (%) 14 (14.3) 7 (14.3)
Surgery and radiotherapy, n (%) 27 (27.6) 4 (8.2)
ADT with surgery and/or radiotherapy, n (%) 20 (20.4) 11 (22.4)
Health service type V = 0.07 .43
Public, n (%) 74 (75.5) 34 (69.4)
Private, n (%) 24 (24.5) 15 (30.6)
d effect size for independent t tests; V effect size for Chi-squared tests; ADT androgen deprivation therapy
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more modest increases in MVPA combined with lower
reductions in sedentary behavior are likely to produce
clinically important changes. These findings are consistent
with those of a systematic review on the effect of exercise
on the quality of life of adult post-treatment cancer sur-
vivors [41]. In this review, the observed mean difference
in EORTC QLQ-C30 physical functioning and fatigue
scores from baseline to up to 12 weeks were 6.23 points
(95 % CI 1.74, 10.72) and -22.45 (95 % CI -50.66,
5.77), respectively. Although this evidence from ran-
domized controlled trials may suggest that engaging in
physical activity enhances physical functioning to a
modest extent [41], our data are open to reverse causa-
tion. That is, it may also be the case that people who
have higher levels of physical functioning participate in
higher levels of physical activity.
Several quality of life scales were associated with
MVPA to a similar or greater extent than physical func-
tioning and fatigue (social functioning, pain, dyspnea,
insomnia, diarrhea, and financial difficulties). Systematic
review evidence on adult post-treatment cancer survivors
suggests that exercise may improve social functioning and
sleep disturbance, but may have no effect on pain [41]. For
breast and colon cancer patients undergoing adjuvant
chemotherapy, however, a recent study has shown that
physical activity can reduce nausea and vomiting, and pain
[42]. Furthermore, some associations may be more plau-
sibly explained as reverse causations; diarrhea, for exam-
ple, may be more likely to decrease someone’s
involvement in physical activity than an increase in
physical activity would be to decrease diarrhea. More work
is needed to identify the circumstances in which physical
activity can be effective in reducing cancer-related symp-
toms. Physical activity may be more effective at times
when patients are experiencing higher levels of symptoms.
The findings support advice within physical activity
guidelines that exceeding the recommended physical
activity levels is likely to provide additional benefits
[38, 39]. The interpretations of several of the adjusted
unstandardized beta coefficients are that clinically impor-
tant improvements in several quality of life scales could be
achieved through engaging in additional MVPA and
reducing sedentary behavior. As prostate cancer emerges at
a time of life when many men are retired and may have
time to undertake more frequent physical activity, pro-
moting programs that increase activity levels and reduce
sedentary behavior may be effective in this population.
The adjusted unstandardized beta coefficients for the
associations between sedentary behavior and quality of life
illustrate the potential importance of reducing sedentary
behavior. Reducing sedentary behavior (e.g., through
standing more and sitting less) by less than 2 h/day was
associated with clinically important improvements inT
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several quality of life scales (physical functioning, role
functioning, dyspnea). As such, reducing sedentary
behavior meaningfully compliments the effects achievable
through increasing MVPA. Our findings are consistent with
those of a systematic review in which emerging evidence
was presented of higher levels of sedentary behavior being
associated with both lower quality of life [43] and greater
risk of depression [44] in adults (not cancer survivors).
Research with cancer populations is mixed, with some
evidence for an association between sedentary behavior
and quality of life [45–48], and other studies showing no
effects [16, 49].
Limitations of this study include ceiling and floor effects
(many data points at the upper and lower limits, respec-
tively, of response scales) for several of the quality of life,
anxiety, and depressive symptoms scales (which attenuated
the magnitudes of correlations observed), the participants’
high levels of functioning, the small sample size, potential
confounding, and the inability of the accelerometers to
detect posture. Men in this study had reasonably high
quality of life scores, and negligible levels of anxiety and
depressive symptoms, thus producing ceiling and floor
effects. The men were highly functioning, with the EORTC
QLQ-C30(V3) scores, for example, being consistently
higher than, but within one standard deviation of, norms for
prostate cancer survivors aged 60–69 years [50]. The men
were also more physically active than other samples of
prostate cancer survivors reported in the literature [5]. Our
exclusion of men with musculoskeletal, cardiovascular, or
neurological disorders that could limit them from exercis-
ing from this study may have been partially responsible for
producing this sample of highly functioning men and the
limited variation in much of our data. The sample size in
this study was small, meaning that the null findings could
have been due to low statistical power and that the reported
findings may be unstable and will require replication with
larger samples. Even so, the use of an objective measure
for assessing physical activity is a major strength of this
study, because measurement error (which can reduce sta-
tistical power [51]) is substantially less with accelerome-
ters compared to physical activity logs and questionnaires
[52]. Although the study was undertaken with data from a
cluster randomized controlled trial, the study reported here
is cross-sectional, meaning that the results are subject to
residual confounding as with any observational study.
Finally, the hip-worn ActiGraph accelerometer was unable
to detect posture, which means that if a participant was
standing still and accumulating\100 CPM, this activity
would be incorrectly classified as sedentary time resulting
in an over-estimation of activity of this intensity [31].
This study is novel in its focus, as it provided a snapshot
of physical activity and time spent sedentary in prostate
cancer survivors using an objective measure, and their
associations with quality of life, anxiety, and depressive
symptoms. The findings suggest it may be possible to
achieve clinically important improvements in quality of life
through increasing MVPA and reducing sedentary behav-
ior. Further research is needed to examine these relation-
ships more closely using objective measures of sitting, such
as the thigh-worn activPAL inclinometer [53]. In addition,
researchers have an opportunity to build on the work
showing, for example, that patterns of sedentary behavior,
such as the frequency of interruptions to sustained bouts of
sitting, influence health outcomes irrespective of the total
volume of sedentary behavior [54]. Future research,
including prospective studies, would ideally involve larger
and more representative samples of prostate cancer sur-
vivors, in terms of their physical, psychological, and social
functioning and their engagement in objectively assessed
physical activity.
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